Vorolanib, also known as CM-082 and X-82, is small molecule dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) with antiangiogenic and antineoplastic activities. VEGFR/PDGFR dual kinase inhibitor Vorolanib inhibits all isoforms of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs are receptor tyrosine kinases that may be upregulated in various tumor cell types. VEGFR/PDGFR dual kinase inhibitor Vorolanib has been shown to reduce tissue toxicity by 95 percent compared with first-generation kinase inhibitors.
MedKoo Cat#: 327032
Name: Vorolanib
CAS#: 1013920-15-4
Chemical Formula: C23H26FN5O3
Exact Mass: 439.2020
Molecular Weight: 439.49
Elemental Analysis: C, 62.86; H, 5.96; F, 4.32; N, 15.94; O, 10.92
The following data is based on the product molecular weight 439.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
